A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT05743075 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

526

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Ensifentrine
DRUG: Placebo

Sponsor

Nuance Pharma (shanghai) Co., Ltd

Collaborators

[object Object]